Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma.

Yoon KJ, Phelps DA, Bush RA, Remack JS, Billups CA, Khoury JD.

PLoS One. 2008;3(11):e3629. doi: 10.1371/journal.pone.0003629. Epub 2008 Nov 3.

2.

Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.

Danks MK, Yoon KJ, Bush RA, Remack JS, Wierdl M, Tsurkan L, Kim SU, Garcia E, Metz MZ, Najbauer J, Potter PM, Aboody KS.

Cancer Res. 2007 Jan 1;67(1):22-5.

3.

Development of a tumor-selective approach to treat metastatic cancer.

Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, Justus KA, Phelps DA, Remack JS, Yoon KJ, Gillespie S, Kim SU, Glackin CA, Potter PM, Danks MK.

PLoS One. 2006 Dec 20;1:e23.

4.

Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.

Yoon KJ, Qi J, Remack JS, Virga KG, Hatfield MJ, Potter PM, Lee RE, Danks MK.

Mol Cancer Ther. 2006 Jun;5(6):1577-84.

5.

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.

Penketh PG, Shyam K, Baumann RP, Remack JS, Brent TP, Sartorelli AC.

Cancer Chemother Pharmacol. 2004 Apr;53(4):279-87. Epub 2003 Dec 24.

PMID:
14704831
6.

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.

Baumann RP, Shyam K, Penketh PG, Remack JS, Brent TP, Sartorelli AC.

Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95. Epub 2003 Dec 17.

PMID:
14685775
7.

Heterogeneous methylation of the O(6)-methylguanine-DNA methyltransferase promoter in immortalized IMR90 cell lines.

Danam RP, Howell SR, Remack JS, Brent TP.

Int J Oncol. 2001 Jun;18(6):1187-93.

PMID:
11351250
8.

A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers.

Herfarth KK, Brent TP, Danam RP, Remack JS, Kodner IJ, Wells SA Jr, Goodfellow PJ.

Mol Carcinog. 1999 Feb;24(2):90-8.

PMID:
10078936
9.
10.

Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene.

Harris LC, Remack JS, Houghton PJ, Brent TP.

Cancer Res. 1996 May 1;56(9):2029-32.

11.

Changes in O6-methylguanine-DNA methyltransferase expression during immortalization of cloned human fibroblasts.

Harris LC, von Wronski MA, Venable CC, Remack JS, Howell SR, Brent TP.

Carcinogenesis. 1996 Feb;17(2):219-24.

PMID:
8625442
12.
13.

In vitro methylation of the human O6-methylguanine-DNA methyltransferase promoter reduces transcription.

Harris LC, Remack JS, Brent TP.

Biochim Biophys Acta. 1994 Mar 1;1217(2):141-6.

PMID:
8110828
14.

Ribozyme-mediated modulation of human O6-methylguanine-DNA methyltransferase expression.

Potter PM, Harris LC, Remack JS, Edwards CC, Brent TP.

Cancer Res. 1993 Apr 15;53(8):1731-4.

15.

A comparison of human O6-methylguanine-DNA methyltransferase promoter activity in Mer+ and Mer- cells.

Harris LC, Potter PM, Remack JS, Brent TP.

Cancer Res. 1992 Nov 15;52(22):6404-6.

16.

The origin of O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells transfected with human DNA.

Tano K, Shiota S, Remack JS, Brent TP, Bigner DD, Mitra S.

Mutat Res. 1991 Sep;255(2):175-82.

PMID:
1922149

Supplemental Content

Loading ...
Support Center